EA201892485A1 - Способ получения соединения диарилтиогидантоина - Google Patents
Способ получения соединения диарилтиогидантоинаInfo
- Publication number
- EA201892485A1 EA201892485A1 EA201892485A EA201892485A EA201892485A1 EA 201892485 A1 EA201892485 A1 EA 201892485A1 EA 201892485 A EA201892485 A EA 201892485A EA 201892485 A EA201892485 A EA 201892485A EA 201892485 A1 EA201892485 A1 EA 201892485A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- producing
- diarylthiohydantoin compound
- compound
- diarylthiohydantoin
- intermediates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
- B01J27/198—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
Описаны способы и промежуточные соединения для получения соединения (X), которое в настоящее время исследуют для лечения рака предстательной железы.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094436P | 2014-12-19 | 2014-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892485A1 true EA201892485A1 (ru) | 2019-07-31 |
Family
ID=55168400
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791390A EA201791390A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
| EA201892485A EA201892485A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
| EA201892487A EA201892487A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
| EA201892486A EA201892486A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791390A EA201791390A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892487A EA201892487A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
| EA201892486A EA201892486A1 (ru) | 2014-12-19 | 2015-12-17 | Способ получения соединения диарилтиогидантоина |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9688655B2 (ru) |
| EP (4) | EP3372586A1 (ru) |
| JP (2) | JP6681902B2 (ru) |
| KR (1) | KR102586059B1 (ru) |
| CN (2) | CN107108507B (ru) |
| AR (1) | AR103228A1 (ru) |
| AU (1) | AU2015364537B2 (ru) |
| BR (1) | BR112017013113B1 (ru) |
| CA (1) | CA2970937A1 (ru) |
| CY (2) | CY1121684T1 (ru) |
| DK (3) | DK3372585T3 (ru) |
| EA (4) | EA201791390A1 (ru) |
| ES (3) | ES2827549T3 (ru) |
| HR (3) | HRP20220750T1 (ru) |
| HU (2) | HUE042409T2 (ru) |
| IL (1) | IL252843B1 (ru) |
| LT (3) | LT3233803T (ru) |
| MA (1) | MA41200B1 (ru) |
| MD (1) | MD3233803T2 (ru) |
| ME (1) | ME03420B (ru) |
| MX (1) | MX2017008179A (ru) |
| NZ (1) | NZ732766A (ru) |
| PH (1) | PH12017501152A1 (ru) |
| PL (3) | PL3372584T3 (ru) |
| PT (3) | PT3372584T (ru) |
| RS (3) | RS63455B1 (ru) |
| SG (4) | SG10201912805SA (ru) |
| SI (3) | SI3372585T1 (ru) |
| TR (1) | TR201904739T4 (ru) |
| TW (4) | TWI683810B (ru) |
| UA (1) | UA123201C2 (ru) |
| WO (1) | WO2016100652A2 (ru) |
| ZA (1) | ZA201704877B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791390A1 (ru) * | 2014-12-19 | 2017-10-31 | Арагон Фармасьютикалз, Инк. | Способ получения соединения диарилтиогидантоина |
| PL3233823T3 (pl) * | 2014-12-19 | 2019-07-31 | Aragon Pharmaceuticals, Inc. | Sposoby wytwarzania związku diarylotiohydantoiny |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| TW201831461A (zh) * | 2017-01-18 | 2018-09-01 | 台灣神隆股份有限公司 | 製備阿帕魯醯胺的方法 |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| CN108383749B (zh) * | 2018-01-30 | 2021-03-09 | 杭州科巢生物科技有限公司 | 阿帕鲁胺的合成方法及其中间体 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| CN108314646B (zh) * | 2018-04-11 | 2021-03-19 | 武汉慧敏科技中心 | 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法 |
| CN109651256A (zh) * | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN110511207A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN110511206A (zh) * | 2019-06-17 | 2019-11-29 | 扬子江药业集团江苏海慈生物药业有限公司 | 芳基-2-硫代海因类化合物中间体、其制备方法及应用 |
| CN113968815A (zh) * | 2020-07-24 | 2022-01-25 | 苏州科伦药物研究有限公司 | 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法 |
| EP4208451A1 (en) | 2020-09-04 | 2023-07-12 | Synthon B.V. | Improved process for preparation of apalutamide |
| CN113402466B (zh) * | 2021-06-18 | 2022-08-16 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法 |
| CN113292535B (zh) * | 2021-06-18 | 2022-07-01 | 南京方生和医药科技有限公司 | 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法 |
| CN115850233A (zh) * | 2021-09-24 | 2023-03-28 | 南京方生和医药科技有限公司 | 一种阿帕鲁胺的合成方法 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN116332907A (zh) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | 一种无定形阿帕他胺的制备方法 |
| CN117645572A (zh) * | 2023-11-23 | 2024-03-05 | 奥锐特药业股份有限公司 | 恩扎卢胺及其中间体的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| PT2656842T (pt) * | 2006-03-27 | 2016-10-04 | Univ California | Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| CN102105451B (zh) * | 2008-05-16 | 2013-11-13 | 塔克达加利福尼亚股份有限公司 | 葡糖激酶活化剂 |
| ES2575215T3 (es) | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| EP3357917A1 (en) * | 2010-02-16 | 2018-08-08 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| SI3329775T1 (sl) * | 2010-02-24 | 2021-09-30 | Medivation Prostate Therapeutics Llc | Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina |
| EP2683694B1 (en) * | 2011-03-10 | 2016-04-27 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| EP2830638B1 (en) * | 2012-03-29 | 2021-05-05 | Schindler, William | Diaspirin crosslinked pegylated hemoglobin |
| JP6469092B2 (ja) * | 2013-05-29 | 2019-02-13 | ヒノバ ファーマシューティカルズ インコーポレイテッド | イミダゾリジンジオン化合物及び薬物組成物 |
| EA201791390A1 (ru) * | 2014-12-19 | 2017-10-31 | Арагон Фармасьютикалз, Инк. | Способ получения соединения диарилтиогидантоина |
-
2015
- 2015-12-17 EA EA201791390A patent/EA201791390A1/ru unknown
- 2015-12-17 CA CA2970937A patent/CA2970937A1/en active Pending
- 2015-12-17 DK DK18169895.2T patent/DK3372585T3/da active
- 2015-12-17 DK DK15823875.8T patent/DK3233803T3/en active
- 2015-12-17 HR HRP20220750TT patent/HRP20220750T1/hr unknown
- 2015-12-17 WO PCT/US2015/066356 patent/WO2016100652A2/en active Application Filing
- 2015-12-17 LT LTEP15823875.8T patent/LT3233803T/lt unknown
- 2015-12-17 SG SG10201912805SA patent/SG10201912805SA/en unknown
- 2015-12-17 EP EP18170050.1A patent/EP3372586A1/en not_active Withdrawn
- 2015-12-17 TR TR2019/04739T patent/TR201904739T4/tr unknown
- 2015-12-17 SI SI201531848T patent/SI3372585T1/sl unknown
- 2015-12-17 SG SG11201704969QA patent/SG11201704969QA/en unknown
- 2015-12-17 KR KR1020177019551A patent/KR102586059B1/ko active IP Right Grant
- 2015-12-17 ES ES18169756T patent/ES2827549T3/es active Active
- 2015-12-17 SG SG10201912802XA patent/SG10201912802XA/en unknown
- 2015-12-17 NZ NZ732766A patent/NZ732766A/en unknown
- 2015-12-17 PT PT181697566T patent/PT3372584T/pt unknown
- 2015-12-17 JP JP2017532725A patent/JP6681902B2/ja active Active
- 2015-12-17 SI SI201530599T patent/SI3233803T1/sl unknown
- 2015-12-17 RS RS20220542A patent/RS63455B1/sr unknown
- 2015-12-17 AU AU2015364537A patent/AU2015364537B2/en active Active
- 2015-12-17 MD MDE20170208T patent/MD3233803T2/ro unknown
- 2015-12-17 ES ES18169895T patent/ES2919951T3/es active Active
- 2015-12-17 SI SI201531433T patent/SI3372584T1/sl unknown
- 2015-12-17 HU HUE15823875A patent/HUE042409T2/hu unknown
- 2015-12-17 PL PL18169756T patent/PL3372584T3/pl unknown
- 2015-12-17 PL PL18169895.2T patent/PL3372585T3/pl unknown
- 2015-12-17 CN CN201580069602.5A patent/CN107108507B/zh active Active
- 2015-12-17 MX MX2017008179A patent/MX2017008179A/es active IP Right Grant
- 2015-12-17 EA EA201892485A patent/EA201892485A1/ru unknown
- 2015-12-17 RS RS20190350A patent/RS58454B1/sr unknown
- 2015-12-17 LT LTEP18169756.6T patent/LT3372584T/lt unknown
- 2015-12-17 EP EP18169756.6A patent/EP3372584B9/en active Active
- 2015-12-17 PL PL15823875T patent/PL3233803T3/pl unknown
- 2015-12-17 ME MEP-2019-86A patent/ME03420B/me unknown
- 2015-12-17 MA MA41200A patent/MA41200B1/fr unknown
- 2015-12-17 IL IL252843A patent/IL252843B1/en unknown
- 2015-12-17 SG SG10201912811QA patent/SG10201912811QA/en unknown
- 2015-12-17 EA EA201892487A patent/EA201892487A1/ru unknown
- 2015-12-17 DK DK18169756.6T patent/DK3372584T5/da active
- 2015-12-17 EA EA201892486A patent/EA201892486A1/ru unknown
- 2015-12-17 ES ES15823875T patent/ES2718539T3/es active Active
- 2015-12-17 PT PT181698952T patent/PT3372585T/pt unknown
- 2015-12-17 BR BR112017013113-7A patent/BR112017013113B1/pt active IP Right Grant
- 2015-12-17 US US14/973,089 patent/US9688655B2/en active Active
- 2015-12-17 HU HUE18169756A patent/HUE052475T2/hu unknown
- 2015-12-17 EP EP15823875.8A patent/EP3233803B1/en active Active
- 2015-12-17 CN CN202410667649.2A patent/CN118638097A/zh active Pending
- 2015-12-17 UA UAA201707588A patent/UA123201C2/uk unknown
- 2015-12-17 PT PT15823875T patent/PT3233803T/pt unknown
- 2015-12-17 RS RS20201378A patent/RS61060B9/sr unknown
- 2015-12-17 EP EP18169895.2A patent/EP3372585B1/en active Active
- 2015-12-17 LT LTEP18169895.2T patent/LT3372585T/lt unknown
- 2015-12-18 TW TW104142692A patent/TWI683810B/zh active
- 2015-12-18 TW TW108131623A patent/TWI689494B/zh active
- 2015-12-18 TW TW108131622A patent/TWI703132B/zh active
- 2015-12-18 TW TW108146841A patent/TWI753336B/zh active
- 2015-12-21 AR ARP150104237A patent/AR103228A1/es unknown
-
2017
- 2017-06-19 PH PH12017501152A patent/PH12017501152A1/en unknown
- 2017-07-18 ZA ZA2017/04877A patent/ZA201704877B/en unknown
-
2019
- 2019-03-19 HR HRP20190540TT patent/HRP20190540T1/hr unknown
- 2019-04-10 CY CY20191100400T patent/CY1121684T1/el unknown
-
2020
- 2020-03-24 JP JP2020052658A patent/JP6903785B2/ja active Active
- 2020-11-02 CY CY20201101031T patent/CY1123611T1/el unknown
- 2020-11-20 HR HRP20201847TT patent/HRP20201847T2/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892485A1 (ru) | Способ получения соединения диарилтиогидантоина | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| EA201791391A1 (ru) | Способы получения соединения диарилтиогидантоин | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| EA201790413A1 (ru) | Антитела против tigit | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| EA201890442A1 (ru) | Получение фоторецепторов для лечения заболеваний сетчатки | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
| EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| EA202091259A1 (ru) | Способ получения опикапона и его интермедиатов | |
| EA201691632A1 (ru) | Пиразины в качестве модуляторов gpr6 | |
| EA201691203A1 (ru) | Твёрдые формы тенофовира | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. | |
| EP3442555A4 (en) | METHODS OF TREATING BREAST CANCER | |
| EA201992022A1 (ru) | Терапевтическая рнк | |
| AU2016902922A0 (en) | Methods of Treating Cancer (I) | |
| AU2016902923A0 (en) | Methods of Treating Cancer (II) |